Organ transplant immunosuppressant drugs have various applications, features, and uses. These drugs are primarily used to prevent organ rejection after transplantation by suppressing the immune system's response. They help lower the risk of the body's immune system attacking and damaging the transplanted organ. Immunosuppressant drugs are tailored to individual patients and their specific transplant procedures. They are essential in increasing the success rate of organ transplantation, improving patient outcomes, and enabling long-term graft survival.
Access Full Report at https://www.databridgemarketresearch.com/reports/colombia-organ-transplant-immunosuppressant-drugs-market
Data Bridge Market Research analyses that the Colombia Organ Transplant Immunosuppressant Drugs Market is valued at USD 0.18 billion in 2022 and is expected to reach USD 0.24 billion by 2030, registering a CAGR of 3.50% during the forecast period of 2023 to 2030. The growth of the organ transplant immunosuppressant drugs market is driven by continuous research and development endeavors aimed at improving the effectiveness and safety of these drugs. Ongoing efforts in enhancing their efficacy and reducing side effects contribute to market expansion and better patient outcomes.
Key Findings of the Study
Increasing demand for organ transplant procedures is expected to drive the market's growth rate
The Colombia organ transplant immunosuppressant drugs market experiences growth due to the increasing demand for organ transplant procedures. As the prevalence of chronic diseases and organ failures rises, the need for transplantation becomes more prominent. To ensure the success of these procedures, immunosuppressant drugs are necessary to prevent organ rejection. This increased demand for organ transplants directly drives the growth of the organ transplant immunosuppressant drugs market, as these drugs are crucial for maintaining graft survival and improving patient outcomes.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2023 to 2030
|
Base Year
|
2022
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
Segments Covered
|
Organ Type (Kidney, Liver, Heart, Lung, Pancreas, Others), Drug Class (Calcineurin Inhibitors, Antimetabolite Immunosuppressants, Steroids, M0TOR Inhibitor, Monoclonal Antibody, Others), Drug Type (Generics, Branded), Route of Administration (Oral, Parenteral), End User (Hospitals, Transplant Centers), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Lilly (U.S.), Merck & Co., Inc. (U.S.), Aurobindo Pharma (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Pfizer Inc.(U.S.), Astellas Pharma Inc.(Japan), Sanofi (France), Novartis AG (Switzerland), Bayer AG (Germany), Dr. Reddy’s Laboratories Ltd.(India), Alkem Labs Ltd (India), Abbott (U.S.)
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The Colombia organ transplant immunosuppressant drugs market is segmented on the basis of organ type, drug type, drug class, route of administration, distribution channel, and end-user.
- On the basis of organ type, the Colombia organ transplant immunosuppressant drugs market is segmented into kidney, liver, heart, lung, pancreas, and others. The Liver segment dominates in Colombia organ transplant immunosuppressant drugs market and is growing at the CAGR of 1.1% in the forecast period of 2023 to 2030 due to several factors. Liver transplants are one of the most common and complex organ transplant procedures, with a high demand globally.
In 2023, the liver segment is dominating the organ type segment of the global organ transplant immunosuppressant drugs market
In 2023, the liver segment is dominating the market and is growing at a CAGR of 1.1% owing to the increasing prevalence of liver diseases and the rising number of liver transplant procedures further strengthening the market presence of immunosuppressant drugs for liver transplantation. The liver's unique immunological characteristics and the need for specialized immunosuppressant drug regimens contribute to the dominance of the liver segment
- On the basis of drug type, the Colombia organ transplant immunosuppressant drugs market is segmented into generics, branded. The generics segment dominates the product segment at CAGR 1.0% in the forecast period 2023 to 2030 as generics are more cost-effective alternatives to branded drugs, making them a preferred choice for patients and healthcare providers.
- 根據藥物類別，哥倫比亞器官移植免疫抑制藥物市場分為鈣調神經磷酸酶抑制劑、抗代謝免疫抑制劑、類固醇、m0tor 抑制劑、單株抗體等。 2023 年，全球器官移植免疫抑制藥物市場的鈣調神經磷酸酶抑制劑部分將以 1.1% 的複合年增長率成長，因為這些藥物可以有效抑制免疫系統，防止器官排斥。
2023 年，鈣調神經磷酸酶抑制劑將在全球器官移植免疫抑制藥物市場佔據主導地位
2023 年，鈣調神經磷酸酶抑制劑在哥倫比亞器官移植免疫抑制藥物市場佔據主導地位，因為這些藥物可以有效抑制免疫系統，防止器官排斥。鈣調神經磷酸酶領域的主導地位歸因於鈣調神經磷酸酶抑制劑的豐富臨床經驗、經過驗證的療效和已建立的安全性，使其成為器官移植患者免疫抑制的首選藥物。
- 根據給藥途徑，哥倫比亞器官移植免疫抑制藥物市場分為口服和腸外給藥。 2023 年，口服藥物將以 1.0% 的複合年增長率主導哥倫比亞器官移植免疫抑制藥物市場，因為口服給藥為患者提供了便利和易用性，允許自我給藥並提高藥物依從性。
- 根據分銷管道，哥倫比亞器官移植免疫抑制藥物市場分為醫院藥房、網路藥房、零售藥房。 2023 年，醫院藥局將以 1.0% 的複合年增長率佔據分銷管道領域的主導地位，因為醫院是進行器官移植手術的主要醫療機構。
- 根據最終用戶，哥倫比亞器官移植免疫抑制藥物市場分為醫院、移植中心。 2023 年，醫院部門將以 1.0% 的複合年增長率佔據最終用戶部門的主導地位，這歸因於醫院在整個器官移植過程中發揮的核心作用，使其成為免疫抑制藥物需求的主要來源。
主要參與者
Data Bridge Market Research 認為以下公司是哥倫比亞器官移植免疫抑制藥物市場的主要參與者，哥倫比亞器官移植免疫抑制藥物市場的主要參與者包括 Teva Pharmaceutical Industries Ltd（以色列）、Mylan NV（美國）、Johnsons & Johnsons Services Inc（美國）、F. Hoffman-La Roche Ltd.（瑞士）、Lilly（美國）
市場開發
- 2020年11月，魯賓製藥近期在美國市場推出了一款名為他克莫司的免疫抑制劑仿製藥。這種藥物專門用於預防同種異體肝臟、腎臟和心臟移植患者的器官排斥。
- 2021年7月，基於一項非干預性研究的真實世界證據，美國食品藥物管理局（FDA）批准了Prograf（他克莫司）的新用途。該藥物目前已獲準與其他免疫抑制藥物合併用於接受肺移植的成人和兒科患者，以防止器官排斥。
- 2020 年 12 月，在獲得美國食品藥物管理局的批准後，魯賓有限公司推出了 500 毫克黴酚酸酯片 USP。此次產品發布是由於 Lupin 的聯盟夥伴 Concord Biotech Limited（Concord）獲得了 ANDA（簡化新藥申請）批准。
- 2020 年 4 月，Lupin Limited 推出了黴酚酸緩釋片 USP，有 180 毫克和 360 毫克兩種規格。這些藥片是諾華製藥公司生產的 Myfortic 緩釋片的仿製藥。此藥物適用於預防接受腎臟移植的成年患者以及腎臟移植後至少 6 個月的 5 歲及以上兒科患者的器官排斥。
- 2022 年 8 月，以開發和製造免疫抑制劑和腫瘤學領域的發酵型 API 而聞名的印度公司 Concord Biotech Limited 向印度證券交易委員會 (SEBI) 提交了其紅鯡魚招股說明書 (DRHP) 草案。此次申請是為了透過首次公開募股（IPO）籌集資金。以 2021 年的銷售市佔率來看，Concord Biotech Limited 已成為業界的傑出參與者。
區域分析
從地理上看，哥倫比亞器官移植免疫抑制藥物市場報告涵蓋的國家包括北美洲的美國、加拿大和墨西哥，歐洲的德國、法國、英國、荷蘭、瑞士、比利時、俄羅斯、義大利、西班牙、土耳其，歐洲其他地區，中國、日本、印度、韓國、新加坡、馬來西亞、澳洲、泰國、印尼、菲律賓，亞太地區（APAC）的其他亞太地區（APAC），沙烏地阿拉伯、阿聯酋、南非、埃及、以色列，中東和非洲（MEA）的其他中東和非洲（MEA）的其他地區，南美洲的巴西、阿根廷和南美洲其他地區。
根據 Data Bridge 市場研究分析：
有關哥倫比亞器官移植免疫抑制藥物市場 報告的更多詳細信息，請點擊此處 - https://www.databridgemarketresearch.com/reports/colombia-organ-transplant-immunosuppressant-drugs-market
